A detailed history of Legal & General Group PLC transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 47,558 shares of EWTX stock, worth $1.41 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
47,558
Previous 47,558 -0.0%
Holding current value
$1.41 Million
Previous $1.27 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$15.88 - $29.5 $98,043 - $182,133
6,174 Added 14.92%
47,558 $1.27 Million
Q2 2024

Aug 14, 2024

BUY
$15.08 - $21.23 $194,426 - $273,718
12,893 Added 45.25%
41,384 $745,000
Q1 2024

May 14, 2024

BUY
$9.25 - $19.97 $109,464 - $236,324
11,834 Added 71.05%
28,491 $519,000
Q4 2023

Feb 15, 2024

BUY
$5.51 - $12.1 $72,329 - $158,836
13,127 Added 371.87%
16,657 $182,000
Q3 2023

Nov 14, 2023

SELL
$5.73 - $7.69 $3,094 - $4,152
-540 Reduced 13.27%
3,530 $20,000
Q2 2023

Aug 14, 2023

BUY
$5.71 - $10.29 $2,489 - $4,486
436 Added 12.0%
4,070 $31,000
Q4 2022

Feb 14, 2023

BUY
$7.58 - $11.08 $8,034 - $11,744
1,060 Added 41.18%
3,634 $32,000
Q3 2022

Nov 14, 2022

BUY
$8.08 - $13.58 $468 - $787
58 Added 2.31%
2,574 $25,000
Q2 2022

Aug 22, 2022

SELL
$5.67 - $9.87 $12,031 - $20,944
-2,122 Reduced 45.75%
2,516 $20,000
Q1 2022

May 16, 2022

SELL
$9.1 - $18.97 $118 - $246
-13 Reduced 0.28%
4,638 $44,000
Q4 2021

Feb 14, 2022

BUY
$14.41 - $22.41 $40,146 - $62,434
2,786 Added 149.38%
4,651 $71,000
Q2 2021

Aug 12, 2021

BUY
$21.33 - $30.25 $39,780 - $56,416
1,865 New
1,865 $40,000

Others Institutions Holding EWTX

About Edgewise Therapeutics, Inc.


  • Ticker EWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 63,171,700
  • Market Cap $1.87B
  • Description
  • Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...
More about EWTX
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.